ArticleBlood advances2021

Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma.

Stephan R Bohl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.